Sodium polystyrene sulphonate (SPS) has been widely used for hyperkalemia management in chronic kidney disease (CKD). However, data on its safety are scarce and ambiguous. A retrospective cohort study based on the nationwide Swedish Renal Registry examined patterns of use and adverse events associated to SPS initiation during follow-up. 3690 patients initiated SPS during follow-up, […]
The increase in kidney transplant activity in Spain in recent years has relied on acceptance of organs from increasingly older donors and donation after circulatory death (cDCD). This has triggered Concerns about outcomes achieved with these elderly cDCD. A single-ceter retrospective study evaluated 87 cDCD-kidney transplant recepients (KTrs), 46 from donors ≥65 years of age and […]
NaPi-IIb, a type II sodium-dependent phosphate transporter, is considered a dominant transporter in rodents for phosphate absorption in the small intestine. However, the regulation of its expression in chronic kidney disease (CKD) is still ambiguous. A recent study measured protein expression level of NaPi-Iib in CKD-rats by mass spectrometry to evaluate the extent of phosphate […]
Antidiuertic hormone (ADH), commonly known for regulating body’s water balance, has recently been linked to osteoporosis during ageing and microgravity/bed rest. This prompted a research on the possible role od ADH in modulating renal calcium excretion. Data for 12 patients with central diabetes insipidus (CDI) and measured 24-h urinary excretion levels of calcium have been […]
Tolvaptan is an oral aquaretic agent which selectively antagonizes arginine vasopressin V2 receptors and increases free water excretion. A total of 124 hemodialyzed patients with preserved diuresis were recruited in a randomized, double-blind, placebo-controlled, Phase 2 trial to assess tolvaptan efficacy and safety. They were randomized to receive oral tolvaptan 15 mg/day or 30 mg/day, or placebo […]
Rituximab (RTX) is an effective remission-induction and maintenance treatment for patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). The major challenge of patient care is the early detection of relapse to prevent organ damage and improve survival in these individuals. A recently published single-center cohort study assessed serial ANCA, CD19+ B-cell status and relapse rate […]
Acute kidney injury (AKI) may occur in 4-23% of patients with COVID-19. Those who require renal replacement therapy have mainly been treated with extracorporeal dialysis. However, peritoneal dialysis (PD) may also be considered as a valuable treatment option in such cases when there is a capacity limit or availability constraint of equipment and supplies for […]
Autosomal dominant polycystic kidney disease (ADPKD) is characterized by the exponential and unlimited enlargement of the total kidney volume (TKV) associated with a decrease in renal function. In the prospective, placebo-controlled tolvaptan efficacy and safety in the management of ADPKD and its outcomes (TEMPO) 3:4 trial a mixed-model repeated-measures analysis was applied to assess a […]
Several studies report direct infection of different types of kidney cells by SARS-CoV-2 detected by transmission electron microscopy (TEM) both on post-mortem analysis and kidney biopsy specimens. However, these studies did not include detection of viral RNA or other methods for viral detection of kidney specimens and thus it is unclear whether the observed particles […]
ERA-EDTA Operative Headquarters
Via XXIV Maggio 38
43123 Parma – Italy
Phone: +39 0521 989078
Fax: +39 0521 959242
E-mail: secretariat@era-edta.org
ERA-EDTA Registered Office
c/o PKF Littlejohn, 15 Westferry Circus, Canary Wharf
London E14 4HD – United Kingdom